Please ensure Javascript is enabled for purposes of website accessibility

Why Affimed N.V. Stock Dropped Today

By Prosper Junior Bakiny - Apr 15, 2021 at 5:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's latest quarterly update was less than impressive.

What happened?

On Thursday, drugmaker Affimed N.V. (AFMD 1.44%) released its earnings report for the fiscal year 2020, which ended on Dec. 31. Investors were not pleased with the company's financial results, however, and its shares fell sharply as a result. Affimed's stock ended the day down by 8.2% after dropping by as much as 12.3% earlier in the trading session.

So what

During the fiscal year 2020, Affimed reported revenue of 28.4 million euros, representing a 32.6% year-over-year increase. On average, analysts were expecting the company's top line to come in at 38.41 million euros. The biotech's bottom-line figure was also a miss.

Affimed recorded a net loss of 41.6 million euros  -- or .50 euros on a per-share basis -- compared to a net loss and a net loss per share of 33 million euros and .50 euros recorded during the previous fiscal year. Analysts were looking for a net loss of .38 euros for Affimed. Given that the biopharmaceutical company badly missed its top- and bottom-line estimates, it isn't surprising that investors ran for the hills following the release of its earnings report. 

Upside down piggy bank.

Image source: Getty Images.

Now what 

Despite Affimed's poor financial results for fiscal year 2020, investors should focus on the company's clinical programs. And on that front, there's been plenty of good news for the healthcare company in recent weeks. For instance, Affimed reported positive results from a preplanned interim futility analysis of a phase 2 clinical trial for AFM13, a potential treatment for relapsed or refractory CD30-positive peripheral T-cell lymphoma. 

Following this win, AFM13 also showed encouraging results in a phase 1 trial in treating patients with Hodgkin's lymphoma. For now, the progress of Affimed's programs probably matters just as much as its financial results, which is why investors shouldn't make much of its fiscal-year 2020 revenue and earnings miss. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Affimed N.V. Stock Quote
Affimed N.V.
AFMD
$2.81 (1.44%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.